Intravenous infusion of mesenchymal stem cells from family donors is safe and improves symptoms like itching, sleep disturbances, and fatigue associated with Recessive Dystrophic Epidermolysis Bullosa (RDEB), according to a clinical trial.
The intravenous infusion of mesenchymal stem cells from family donors is safe and effectively alleviates symptoms such as pruritus (itching), sleep disturbances, and fatigue in patients suffering from Recessive Dystrophic Epidermolysis Bullosa (RDEB), commonly known as "butterfly skin." This promising result comes from a clinical trial conducted by researchers at the Universidad Carlos III de Madrid (UC3M), the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) of the Ministry of Science, Innovation and Universities, the Fundación Jiménez Díaz Health Research Institute (IIS-FJD), the CIBER Rare Diseases (CIBERER), and La Paz University Hospital in Madrid. The trial suggests that these stem cells may offer a new treatment option for patients with this debilitating condition, which is characterized by fragile skin that easily tears and blisters.
The study involved 15 adult RDEB patients who received intravenous infusions of mesenchymal stem cells from their family donors over the course of six months. The researchers evaluated various symptoms including pruritus (itching), sleep disturbances, fatigue, pain, and overall quality of life before and after treatment. They found that the infusion significantly reduced itchiness and improved sleep patterns for most patients. Additionally, there was a notable improvement in physical activity levels and an increase in their ability to perform daily tasks.
"This trial represents a significant step forward in treating RDEB," said Dr. Ana María Sánchez, lead researcher from UC3M. "The use of family-donor stem cells is not only safe but also shows promising results for symptom relief."
RDEB is a rare genetic disorder that affects approximately 1 in every 50,000 births worldwide. The condition causes severe blistering and skin fragility, leading to chronic pain, scarring, and impaired mobility. Currently, there are no approved treatments specifically designed to address the underlying issues of RDEB.
The findings from this clinical trial highlight the potential for stem cell therapy as a viable treatment option for patients with RDEB. Further research is needed to confirm these results and determine the long-term effects of mesenchymal stem cell infusions on patient outcomes.
